Strides Pharma Science’s step-down wholly owned subsidiary — Strides Pharma Global Pte, Singapore has entered into an exclusive product development, licensing and supply agreement with SUDA Pharmaceuticals for its novel drug SUD-001H, an oral spray of sumatriptan to treat migraine headache for the US market.
Execution of Strides’ generic product pipeline for the US is nearing completion and is expected to have 150 plus ANDA filings by 2021. The company is now focusing on developing a portfolio of complex and specialty products including products filed under the 505B (2) regulatory pathway.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.